| Literature DB >> 32218209 |
Carmen Limban1, Mariana Carmen Chifiriuc2, Miron Teodor Caproiu3, Florea Dumitrascu3, Marilena Ferbinteanu4, Lucia Pintilie5, Amalia Stefaniu5, Ilinca Margareta Vlad1, Coralia Bleotu6, Luminita Gabriela Marutescu2, Diana Camelia Nuta1.
Abstract
The increasing threat of antimicrobial resistance to all currently available therapeutic agents has urged the development of novel antimicrobials. In this context, a series of new benzoylthiourea derivatives substituted with one or moreEntities:
Keywords: X-ray; antibiofilm; antimicrobial; benzoylthiourea derivatives; in silico
Mesh:
Substances:
Year: 2020 PMID: 32218209 PMCID: PMC7180980 DOI: 10.3390/molecules25071478
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Antimicrobial thiourea derivatives.
Scheme 1Synthesis of the new derivatives (5a–g).
Figure 2View of the asymmetric unit for 5d with the atom numbering scheme (50% probability ellipsoid).
Figure 3Details of supramolecular interactions in the crystal packing of 5d.
Figure 4Highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) surfaces of 5d compound.
Figure 5(a) The optimized geometry and electrostatic potential pattern of the surface of compound 5d (red, negative, high electron density; blue, positive area, low electron density). (b) The optimized geometry and local ionization potential map of compound 5d. (c) The optimized geometry and LUMO map of compound 5d.
Figure 6Molecular docking studies with the 4DUH receptor. (a) Binding site and docking pose of the co-crystallized ligand interacting with residues. (b) Hydrogen bonds between the residues of the ARG 136, ARG 76, GLT 101 and ASP 73 and the co-crystallized. (c) Docking validation of co-crystallized ligand. (d) Hydrogen bonds between the residues of the GLY 101 and the 5d ligand. (e) Docking validation of 5d. (f) Docking pose of the 5d interacting with residues in the binding site. (g) Hydrogen bonds between the residues of the ASN 46, ILE 78, GLY 77 and the 5e ligand. (h) Docking validation of 5e. (i) Docking pose of the 5e interacting with residues in the binding site.
Figure 7Docking pose of the new benzoylthiourea derivatives in the binding site of 4DUH. (a) The derivatives with the similar binding mode of the co-crystallized (brown): 5b, light green; 5c, ice blue; 5d, sky blue; 5f, brick. (b) The derivatives with a different binding mode from the co-crystallized (5a, nut brown; 5e, blue; 5g, soft pink).
Ligands’ molecular properties values.
| Compound | Atoms | Weight [Daltons] | Flexible Bonds | Lipinski Violations | Hydrogen Donors | Hydrogen Acceptors | LogP ** |
|---|---|---|---|---|---|---|---|
| Co-crystallized * | 41 | 387.46 | 6 | 1 | 2 | 7 | 5.10 |
|
| 50 | 408.49 | 6 | 1 | 2 | 4 | 5.52 |
|
| 50 | 444.47 | 6 | 1 | 2 | 4 | 5.72 |
|
| 50 | 444.47 | 6 | 1 | 2 | 4 | 5.72 |
|
| 50 | 444.47 | 6 | 1 | 2 | 4 | 5.72 |
|
| 50 | 447.47 | 6 | 1 | 2 | 4 | 5.72 |
|
| 53 | 458.50 | 7 | 1 | 2 | 4 | 6.31 |
|
| 53 | 458.50 | 7 | 1 | 2 | 4 | 6.31 |
* co-crystallized: 4-{[4’-methyl-2’-(propanoylamino)-4,5’-bi-1,3-thiazol-2-yl]amino}benzoic acid. ** The log P calculation was performed using the XLOGP3-AA method [54].
The inhibitory activity of the new F-compounds 5a–g on the planktonic growth of the tested microbial strains. The minimum inhibitory concentration (MIC) expressed in µg/mL of the new fluoro compounds (5a–g) are presented as the average of three different experiments. The most active compounds are highlighted.
| 5a | 5b | 5c | 5d | 5e | 5f | 5g | |
|---|---|---|---|---|---|---|---|
| 128 | 128 | >256 | 128 | 128 | >256 | 128 | |
| 128 | 128 | >256 | >256 | >256 | >256 | >256 | |
| >128 | >128 | >128 | >128 | >128 | >128 | >128 | |
| 128 | >256 | >256 | >256 | >256 | >256 | >256 | |
| >128 | >128 | >128 | >128 | >128 | >128 | >128 | |
| >128 | >128 | >128 | 64 | >128 | >128 | >128 |
The inhibitory activity of the new F-compounds 5a–g on the microbial biofilm development on the inert substratum (the most active compounds are highlighted).
| 5a | 5b | 5c | 5d | 5e | 5f | 5g | |
|---|---|---|---|---|---|---|---|
| A | A | A | A | I | A | I | |
| A | I | I | I | I | I | I | |
| I | A | I | A | A | A | I | |
| I | I | I | I | I | I | I | |
| I | A | I | A | A | I | A | |
| I | A | A | I | I | I | I |
I: Inhibitory activity on the biofilm development. A: Absence of any inhibitory activity on the biofilm development.